Shire plc Shire Plc : Director/Pdmr Shareholding

Features Dow Jones Newswires


Continue Reading Below

Director/PDMR Shareholding

August 9, 2017

- Shire plc (LSE: SHP, NASDAQ: SHPG)

Notification of transaction by person discharging managerial

responsibilities and person closely associated with them

Continue Reading Below

Details of the person discharging managerial responsibilities

1. ("PDMR") / person closely associated them ("PCA")

a) Name Kim Stratton / Peter Stratton

2. Reason for the notification

Head of International Commercial (PDMR) / PCA of Kim

a) Position / status Stratton

Initial notification /

b) amendment Initial notification

Details of the issuer, emission allowance participant,

3. auction platform, auctioneer or auction monitor

a) Name Shire plc

b) LEI 54930005LQRLI2UXRQ59

Details of the transaction(s): section to be repeated

for (i) each type of instrument; (ii) each type of

transaction; (iii) each date; and (iv) each place

4. where transactions have been conducted

Description of the

financial instrument, Shire plc Ordinary Shares of 5 pence each ("Ordinary

a) type of instrument Shares")

Identification code ISIN: JE00B2QKY057

Transfer of Ordinary Shares held by Kim Stratton to

a joint account held by Kim Stratton and Peter Stratton

Nature of the and the pledge of such Ordinary Shares as security

b) transaction for a loan.

c) Price(s) and volume(s) Price(s) Volume(s)

N/A 5,943

d) Aggregated information N/A (single transaction)

- Aggregated volume

- Price

e) Date of the transaction August 8, 2017

f) Place of the Outside a trading venue


Oliver Strawbridge

Senior Assistant Company Secretary

For further information please contact:

Investor Relations

Ian Karp +1 781 482 9018

Robert Coates +44 1256 894874


Lisa Adler +1 617 588 8607

Debbi Ford +1 617 949 9083


About Shire

Shire is the leading global biotechnology company focused on serving

people with rare diseases. We strive to develop best-in-class products,

many of which are available in more than 100 countries, across core

therapeutic areas including Hematology, Immunology, Neuroscience,

Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal

Medicine / Endocrine and Hereditary Angioedema; and a growing franchise

in Oncology.

Our employees come to work every day with a shared mission: to develop

and deliver breakthrough therapies for the hundreds of millions of

people in the world affected by rare diseases and other high-need

conditions, and who lack effective therapies to live their lives to the


This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Shire plc via Globenewswire

(END) Dow Jones Newswires

August 09, 2017 09:30 ET (13:30 GMT)